Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals VRTX. And retail traders should know. We noticed this today when the trades showed up on publicly ...

Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Vertex Pharmaceuticals (NASDAQ:VRTX) in the last three months. In the table below ...

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) have appreciated more than 40% since I shifted my coverage to hold/neutral last year, and I am not surprised since the company executed ...

Vertex Pharmaceuticals again raised its full-year outlook after posting earnings and revenue growth in the third quarter. The biotechnology company on Monday posted a quarterly net profit of $1.05 ...

Vertex Pharmaceuticals (VRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VRTX broke through the 20-day moving average ...

In the preceding three months, 19 analysts have released ratings for Vertex Pharmaceuticals VRTX, presenting a wide array of perspectives from bullish to bearish. The table below provides a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart Arbuckle; Chief Operating Officer, Executive Vice President; Vertex Pharmaceuticals Inc Charles ...

Vertex Pharmaceuticals Inc. ( (VRTX)) has released its Q3 earnings. Here is a breakdown of the information Vertex Pharmaceuticals Inc. presented to its investors. Vertex Pharmaceuticals Inc., a ...

Phil Nadeau, an analyst from TD Cowen, maintained the Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The associated price target remains the same with $525.00. Phil Nadeau’s ...